Biomaterial Database

[Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension]. 1983

C Tosti-Croce, and R Mantellini, and P Fanti, and F Sciarra

A group of 13 male and 8 female out-patients (mean age: 40.57 years), with primary arterial hypertension, was submitted to two periods of treatment in a cross-over study with spironolactone and potassium canrenoate. Each preparation was given at the dose of 200 mg/day per os for 21 days, with a 10-day interval between treatments. Both preparations proved active on the systolic and diastolic pressure values controlled 7 days. However, potassium canrenoate showed a greater and more rapid effect, particularly on diastolic arterial pressure, as also demonstrated by the statistical analyses. PRA and aldosteronemia increased with both treatments, but this increase resulted significantly lower with potassium canrenoate. The minor stimulating action on the renin-angiotensin-aldosterone mechanism by potassium canrenoate may be the reason for its greater anti-hypertensive effect. Both treatments were perfectly tolerated locally and systemically.

UI	MeSH Term	Description	Entries
D006973	Hypertension	Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D011245	Pregnadienes	Pregnane derivatives containing two double bonds anywhere within the ring structures.
D012083	Renin	A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19.	Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794	Blood Pressure	PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.	Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002191	Canrenoic Acid	A synthetic pregnadiene derivative with anti-aldosterone activity.	Canrenoate Potassium,Potassium Canrenoate,17-Hydroxy-3-Oxo-17alpha-Pregna-4,6-Diene-21-Carboxylic Acid,Kalium-Can.-Ratiopharm,SC-14266,Soldactone,Soludactone,Spiroctan,17 Hydroxy 3 Oxo 17alpha Pregna 4,6 Diene 21 Carboxylic Acid,Acid, 17-Hydroxy-3-Oxo-17alpha-Pregna-4,6-Diene-21-Carboxylic,Acid, Canrenoic,Canrenoate, Potassium,Kalium Can. Ratiopharm,SC 14266,SC14266
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D005260	Female		Females
D006339	Heart Rate	The number of times the HEART VENTRICLES contract per unit of time, usually per minute.	Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse